Cicloprofen is fluorene derivative patented by American pharmaceutical company E. R. Squibb as anti-inflammatory agents. Cicloprofen is potent cyclooxygenase inhibitor. Cicloprofen undergoes hydroxylation of the fluorene rings and conjugation with glucuronic acid or sulfate and metabolic transformation leading to stereospecific inversion of the ( - )-enantiomer of Cicloprofen to its (+)-antipode

Drocinonide is a synthetic glucocorticoid used as anti-inflammatory agent. It was shown that drocinonide phosphate potassium is effective ocular anti-inflammatory agent that does not show a strong tendency to elevate the intra-ocular pressure. Drocinonide phosphate potassium forms an insoluble complex with neomycin sulfate in aqueous solution. Dibasic sodium phosphate can be employed in an ophthalmic formulation to prevent the formation of this precipitate without affecting the stability of the steroid or the bioactivity of the antibiotic.

Pentomone is a nonsteroidal antiandrogen developed by Lilly Company for postmenopausal patients with metastatic breast cancer who have been previously treated with tamoxifen. It is a prostate growth inhibitor.

Fluorescein isothiocyanate (FITC) is widely used to attach a fluorescent label to proteins via the amine group. The isothiocyanate group reacts with amino terminal and primary amines in proteins. It has been used for the labeling of proteins including antibodies and lectins. Isomer I (Fluorescein 5-isothiocyanate) has the thiocyanate group on the 4 carbon of the benzene ring, whereas isomer II (Fluorescein 6-isothiocyanate) has the thiocyanate on the 5 carbon. The two isomers are indistinguishable spectrally, either by wavelength or intensity. Isomer I is more easily isolated in pure form, so is less expensive. This may explain why isomer I is more commonly used for labeling. For many purposes, however, the mixed isomers of FITC will be perfectly suitable. Some FITC conjugates are being investigated for diagnostic purposes. Folate-fluorescein isothiocyanate, or folate-FITC, also identified as EC-17, targets folate receptors over expressed in certain cancers and could help in better identifying the margins of the cancer thereby achieving negative margins.

Picoprazole is substituted benzimidazole. Picoprazole inhibited the gastric (H+ + K+)-ATPase in a concentration-and time-dependent manner, which may explain its inhibitory action on acid secretion in vitro and in vivo. This compound inhibits acid secretion at the level of the parietal cell by its ability to inhibit the gastric proton pump. Picoprazole affects pepsin secretion probably indirectly via its effect on the parietal cell. Studies on the (Na+ + K+)-ATPase indicated that this enzyme was unaffected by picoprazole.

Idremcinal (previously known as EM574), a motilin receptor agonist, has been studied for the treatment of gastritis. The drug was involved in phase II in Japan for the treatment of chronic gastritis and Gastro-esophageal reflux in the USA. However, the development of the drug was discontinued.

Phenomorphan is the μ-opioid receptor agonist. Phenomorphan is a synthetic narcotic analgesic structurally related to racemorphan and racemethorphan. It has no accepted medicinal value in the United States.

Ipragratine is azabicyclo[3.3.1]nonyl derivative patented by German pharmaceutical company Boehringer Ingelheim G.m.b.H. as central anticholinergics and spasmolytics.

Mipragoside (also known as AGF 44), an isopropyl ester of monosialoganglioside GM1 that was developed as an anti-inflammatory agent. The topical treatment by this drug improved symptoms of patients with vernal keratoconjunctivitis. Mipragoside was in phase I in Italy for the treatment of inflammation; however, this study was discontinued.

Osanetant (SR-142801) is a NK3 receptor antagonist, it has a higher affinity for human and guinea pig NK3 receptors than for rat NK3 receptors. Osanetant was under development for the treatment of schizophrenia and other Central Nervous System (CNS) disorders. It was developed by Sanofi-Aventis (formerly Sanofi-Synthelabo). Sanofi was originally investigating its potential use as a treatment for psychosis and anxiety. Following phase IIa clinical trials, osanetant entered phase IIb development in February 2001. In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. This follows an earlier decision to discontinue development of eplivanserin for schizophrenia.